Diprosalic oinment 30g (Salicylic acid) — Made in Belgium — Free Delivery

The preparation is not used in ophthalmology; contact with the eyes, mucous membranes, wound surfaces and ulceration should be avoided. if irritation or hypersensitivity occurs during the use of the preparation, treatment should be discontinued. in case of infection, appropriate therapy should be prescribed.

When dandruff or keratinization disappears, treatment is continued only with corticosteroids. Any side effects that are detected with the systemic use of corticosteroids, including inhibition of the function of the adrenal cortex, can also be observed with local administration of corticosteroids, especially in children. Systemic absorption of corticosteroids or salicylic acid when applied topically increases when applied to large body surfaces or when using an occlusive dressing. In such cases, as well as with prolonged use of the preparation, caution should be exercised, especially when treating children.

If excessive dryness or irritation of the skin develops, the preparation should be discontinued.

GCS for topical use can contribute to the onset of psoriasis, including the recurrence of symptoms with the subsequent development of tolerance, the risk of developing pustular psoriasis and local systemic toxicity due to a decrease in the protective function of the skin. Patients with impaired liver function are more susceptible to negative systemic effects. Constant monitoring of such patients is required.

GCS for local use can distort the clinical picture of the disease.

A relapse of the disease is possible if treatment is interrupted. It is also possible to exacerbate the infection and slow down the healing process. The preparation should not be applied to mucous membranes or skin around the eyes due to the keratolytic action of salicylic acid. It is contraindicated to apply the preparation to areas with skin atrophy.

Diprosalik in the form of a lotion is not used under occlusive dressings.

Use during pregnancy and lactation. The safety of using topical GCS during pregnancy has not been established, and therefore the use of the preparation is possible when the expected benefit to the mother outweighs the potential threat to the fetus. Preparationin this group are contraindicated for pregnant women in high doses for a long time.

It has not been established whether GCS for topical use due to systemic absorption can penetrate into breast milk, therefore, a decision should be made to stop breastfeeding or to discontinue the use of the preparation.

Children. The preparation is used in children over the age of 2 years. In children, there may be a more frequent occurrence of signs of suppression of the hypothalamic-pituitary-adrenal system when using local GCS than in adult patients, which is associated with a higher absorption of the preparation due to the greater value of the ratio of skin area to body weight. In children, with local application of GCS, suppression of adrenal function, Cushing's syndrome, growth retardation, insufficient increase in body weight, and increased intracranial pressure were noted.

Manifestations of suppression of the adrenal cortex: a decrease in the level of cortisol in the blood plasma and the absence of a reaction to the sample when stimulating the adrenal glands with the use of ACTH preparations. An increase in intracranial pressure is manifested by protrusion of the crown, headache, bilateral edema of the optic nerve head.

The use of the preparation is possible only when the expected benefit outweighs the potential risk of adverse reactions.

The preparation does not affect the reaction rate when driving or operating other mechanisms.